Literature DB >> 14759560

Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A.

Nicholas E Preece1, Minh Nguyen, Manjula Mahata, Sushil K Mahata, Nitish R Mahapatra, Igor Tsigelny, Daniel T O'Connor.   

Abstract

Previous modeling (PDB 1cfk) of the catecholamine release-inhibitory "catestatin" region of chromogranin A (CgA) suggested a beta-strand/loop/beta-strand active conformation, displaying an electropositive Arg-rich loop (R(351)AR(353)GYGFR(358)). To explore this possibility, we studied NMR structures of linear and cyclic synthetic catestatin, bovine (bCgA(344-364)) or human (hCgA(352-372)). By 2-D (1)H-NMR, the structure of linear catestatin (hCgA(352-372)) exhibited the NOE pattern of a coiled loop (PDB 1lv4). We then constrained the structure, cyclizing the putative Arg-rich loop connecting the beta-strands: cyclic bCgA(350-362) ([C(0)]F(350)RARGYGFRGPGL(362)[C(+14)]). Favored conformations of cyclic bCgA(350-362) were determined by (1)H-NMR and (13)C-NMR spectroscopy. Cyclic bCgA(350-362) conformers (PDB 1n2y) adopted a "twisted-loop" conformation. Alignment between the homology model and the cyclic NMR structure showed that, while portions of the NMR structure's mid-molecule and carboxy-terminus were congruent with the homology model (RMSD, 1.61-1.91 A), the amino-terminal "twisted loop" coiled inward and away from the model (RMSD, 3.36 A). Constrained cyclic bCgA(350-362) did not exert nicotinic cholinergic antagonist activity (IC(50)>10 microM), when compared to full-length linear (IC(50) approximately 0.42-0.56 microM), or cyclic (IC(50) approximately 0.74 microM) catestatin. Thus, loss of activity in the small, constrained peptide did not result from either [Cys]-extension or cyclization, per se. While linear catestatin displays coiled character, a small cyclic derivative lost biological activity, perhaps because its amino-terminal domain deviated sharply from the predicted active conformation. These results refine the relationship between structure and function in catestatin, and suggest goals in future peptidomimetic syntheses, in particular attempts to constrain the correct amino-terminal shape for biological activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14759560     DOI: 10.1016/j.regpep.2003.10.035

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  6 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

2.  Pore formation induced by an antimicrobial peptide: electrostatic effects.

Authors:  Frantz Jean-François; Juan Elezgaray; Pascal Berson; Pierre Vacher; Erick J Dufourc
Journal:  Biophys J       Date:  2008-09-26       Impact factor: 4.033

3.  Functional genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits.

Authors:  Bhavani S Sahu; Jagan M Obbineni; Giriraj Sahu; Prasanna K R Allu; Lakshmi Subramanian; Parshuram J Sonawane; Pradeep K Singh; Binu K Sasi; Sanjib Senapati; Samir K Maji; Amal K Bera; Balashankar S Gomathi; Ajit S Mullasari; Nitish R Mahapatra
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

4.  Variability in secondary structure of the antimicrobial peptide Cateslytin in powder, solution, DPC micelles and at the air-water interface.

Authors:  Frantz Jean-François; Lucie Khemtémourian; Benoît Odaert; Sabine Castano; Axelle Grélard; Claude Manigand; Katell Bathany; Marie-Hélène Metz-Boutigue; Erick J Dufourc
Journal:  Eur Biophys J       Date:  2007-07-07       Impact factor: 1.733

5.  The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury.

Authors:  Katherine A Radek; Belen Lopez-Garcia; Melanie Hupe; Ingrid R Niesman; Peter M Elias; Laurent Taupenot; Sushil K Mahata; Daniel T O'Connor; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2008-01-10       Impact factor: 8.551

6.  Regulation of intestinal SGLT1 by catestatin in hyperleptinemic type 2 diabetic mice.

Authors:  Jessica A Dominguez Rieg; Venkat R Chirasani; Hermann Koepsell; Sanjib Senapati; Sushil K Mahata; Timo Rieg
Journal:  Lab Invest       Date:  2015-11-09       Impact factor: 5.662

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.